Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-582949 and Methotrexate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BMS-582949 and Methotrexate | DRUG | - |
Inclusion Criteria: * Age 18-70 years * Diagnosis of RA for ≥6 months * Swollen or tender joint or ESR \>ULN. Subject must be on stable doses of MTX * Women of Childbearing Potential Exclusion Criteria: * Serum transaminase levels \>ULN * CK\>ULN * Cannot have taken Orencia or Remicade within 8 w...
Top 20 of 28 competitors
BMS-582949 is an investigational small molecule being studied for the treatment of psoriasis, rheumatoid arthritis, and vascular diseases such as atherosclerosis. It has been evaluated in clinical trials for these conditions, though it is not approved and remains in clinical development.
BMS-582949 is a p38 kinase inhibitor, as indicated in a clinical trial title for treating atherosclerosis. It works by inhibiting p38 kinase, an enzyme involved in inflammatory signaling pathways relevant to the diseases under study.
BMS-582949 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company has sponsored clinical trials of the drug across multiple indications.
BMS-582949 has completed Phase 2 clinical trials for psoriasis, rheumatoid arthritis, and vascular diseases. It is an investigational drug and has not been approved by regulatory authorities, as it remains in clinical development.
BMS-582949 has been studied in several completed trials. These include NCT00162292, a Phase 1 multiple ascending dose study in rheumatoid arthritis; NCT00399906, a Phase 2 trial in plaque psoriasis; NCT00570752, a Phase 2 study in atherosclerosis; and NCT00605735, a Phase 2 proof-of-concept trial in rheumatoid arthritis.
BMS-582949 is the sole name provided for this investigational compound. No alternative names have been identified in the available information, so it is not known to be the same as any other marketed or investigational drug.